Similarly, C3-targeted therapeutics (both C3 convertase inhibitors and C3a antagonists) are specifically attractive for metastatic disease given the role of C3 in driving edema after radiation, which is routinely used for these tumors, as well as the role of C3 in leptomeningeal spread. This evidence concerns the gene C3 and metastatic neoplasm.